Growth & profitability
- Revenue has grown 31.9% per year over the past 2 years.
- Net income has grown faster than revenue (90.7% vs 31.9% per year).
3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $33M | $1M | 62.8% | 0.0% | — | — | $8M |
| 2024 | $19M | $670477 | 79.2% | 0.0% | — | — | $8M |
| 2023 | $19M | — | 88.0% | 0.0% | — | — | $2M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $9M | -$2M | 51.4% | 0.0% | — | — | $10M |
| Dec '25 | $8M | -$302557 | 55.0% | 0.0% | — | — | $8M |
| Sep '25 | $8M | $452176 | 60.6% | 0.0% | — | — | $8M |
| Jun '25 | $9M | $630631 | 67.7% | 0.0% | — | — | $8M |
| Mar '25 | $8M | $498592 | 66.8% | 0.0% | — | — | $8M |
| Dec '24 | $5M | -$144152 | 77.4% | 0.0% | — | — | $8M |
| Sep '24 | $4M | $376086 | 78.0% | 0.0% | — | — | — |
| Jun '24 | $5M | $338007 | 80.5% | 0.0% | — | — | — |
| Mar '24 | $5M | $100536 | 80.7% | 0.0% | — | — | — |
How the market has priced HIT against its own fundamentals since 2024-12 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 2 years, Health In Tech, Inc.'s revenue has grown 31.9% per year, and net income grown 90.7% per year. These are computed facts, not advice.
As of FY2025, Health In Tech, Inc. reported — of total debt against $8M of cash.
In FY2025, gross margin was 62.8%, operating margin —, and net margin 3.8%.
As of Jun '26, Health In Tech, Inc. traded at a price-to-earnings ratio of about 44.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.